Intelligence Feed event · Macro · 2026-10-12

    BridgeBio reports positive Phase 3 CALIBRATE trial results in ADH1

    Question

    BridgeBio reports positive Phase 3 CALIBRATE trial results in ADH1

    Direct answer

    BridgeBio Pharma released primary endpoint results from the Phase 3 CALIBRATE clinical study testing encaleret for ADH1 treatment. The trial demonstrated a 91% PTH normalization rate in the treatment arm compared to 0% for standard of care. Additionally, 100% of patients receiving encaleret reported symptom relief versus 46% in the control arm, clearing a critical hurdle toward regulatory submission.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “BridgeBio reports positive Phase 3 CALIBRATE trial results in ADH1”, revision 1, evidence through 2026-10-12. https://marketontology.com/market-events/2026-10-12/bridgebio-reports-positive-phase-3-calibrate-trial-results-in-adh1-db22cd

    MACRO
    BridgeBio reports positive Phase 3 CALIBRATE trial results in ADH1
    BridgeBio Pharma released primary endpoint results from the Phase 3 CALIBRATE clinical study testing encaleret for ADH1 treatment. The trial demonstrated a 91% PTH normalization rate in the treatment arm compared to 0% for standard of care. Additionally, 100% of patients receiving encaleret reported symptom relief versus 46% in the control arm, clearing a critical hurdle toward regulatory submission.
    BBIO
    Impact
    71
    OCT 12
    SIG
    90%
    BBIO
    BridgeBio reports positive Phase 3 CALIBRATE trial results in ADH1
    BridgeBio Pharma released primary endpoint results from the Phase 3 CALIBRATE clinical study testing encaleret for ADH1 treatment. The trial demonstrated a 91% PTH normalization rate in the treatment arm compared to 0% for standard of care. Additionally, 100% of patients receiving encaleret reported symptom relief versus 46% in the control arm, clearing a critical hurdle toward regulatory submission.
    → Statistically significant Phase 3 primary endpoint achievement accelerates FDA regulatory approval and commercial drug revenue timelines.
    Impact
    BridgeBio Pharma released primary endpoint results from the Phase 3 CALIBRATE clinical study testing encaleret for ADH1 treatment. The trial demonstrated a 91% PTH normalization rate in the treatment arm compared to 0% for standard of care. Additionally, 100% of patients receiving encaleret reported symptom relief versus 46% in the control arm, clearing a critical hurdle toward regulatory submission.
    Affected
    BBIO
    Transmission
    Statistically significant Phase 3 primary endpoint achievement accelerates FDA regulatory approval and commercial drug revenue timelines.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BBIOcommercial pipeline valuation and regulatory approval probability repricingUp1-5d91% normal PTH levels achieved in Phase 3 CALIBRATE study vs 0% on standard care.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    BBIOUpdisagreed65.75 2026-10-12-3.73%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month